Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis.

Sackner-Bernstein J, Kanter D, Kaul S.

PLoS One. 2015 Oct 20;10(10):e0139817. doi: 10.1371/journal.pone.0139817. eCollection 2015.

2.

What is the greatest regulatory challenge in the translation of biomaterials to the clinic?

Prestwich GD, Bhatia S, Breuer CK, Dahl SL, Mason C, McFarland R, McQuillan DJ, Sackner-Bernstein J, Schox J, Tente WE, Trounson A.

Sci Transl Med. 2012 Nov 14;4(160):160cm14. doi: 10.1126/scitranslmed.3004915.

PMID:
23152323
3.

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.

O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators.

Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Erratum in: Am Heart J. 2012 May;163(5):900.

PMID:
20435194
4.

Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure.

Maurer MS, Sackner-Bernstein JD, El-Khoury Rumbarger L, Yushak M, King DL, Burkhoff D.

Circ Heart Fail. 2009 May;2(3):189-96. doi: 10.1161/CIRCHEARTFAILURE.108.806240. Epub 2009 Apr 14.

5.

Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.

Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; ESSENTIAL Investigators.

Eur Heart J. 2009 Dec;30(24):3015-26. doi: 10.1093/eurheartj/ehp338. Epub .

6.

Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.

Udelson JE, Pressler SJ, Sackner-Bernstein J, Massaro J, Ordronneau P, Lukas MA, Hauptman PJ.

J Card Fail. 2009 Jun;15(5):385-93. doi: 10.1016/j.cardfail.2008.12.010. Epub 2009 Feb 12.

PMID:
19477398
7.

Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.

Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2008 Jun 11;299(22):2656-66. doi: 10.1001/jama.299.22.2656.

PMID:
18544725
8.

Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline.

Fonarow GC, Abraham WT, Gheorghiade M, Cannon CP, Sackner-Bernstein JD, Udelson JE, Konstam MA; Postmyocardial Infarction Consensus Guideline Committee.

Crit Pathw Cardiol. 2003 Dec;2(4):239-46. doi: 10.1097/01.hpc.0000099743.53432.a8. No abstract available.

PMID:
18340127
9.

Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Sackner-Bernstein J, Aaronson KD.

Curr Cardiol Rep. 2007 May;9(3):187-93. Review.

PMID:
17470331
10.

Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.

Hauptman PJ, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Udelson JE; CASPER Investigators.

Am J Cardiol. 2006 Oct 2;98(7A):60L-66L. Epub 2006 Aug 28.

PMID:
17023234
11.

Risk of death associated with nesiritide in patients with acutely decompensated heart failure.

Aaronson KD, Sackner-Bernstein J.

JAMA. 2006 Sep 27;296(12):1465-6. No abstract available.

PMID:
17003394
12.
13.

Nesiritide--not verified.

Sackner-Bernstein J, Aaronson KD.

N Engl J Med. 2005 Oct 6;353(14):1525-7; author reply 1525-7. No abstract available.

14.

Management of diuretic-refractory, volume-overloaded patients with acutely decompensated heart failure.

Sackner-Bernstein JD.

Curr Cardiol Rep. 2005 May;7(3):204-10. Review.

PMID:
15865862
15.
16.

Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.

Sackner-Bernstein JD, Skopicki HA, Aaronson KD.

Circulation. 2005 Mar 29;111(12):1487-91. Epub 2005 Mar 21. Erratum in: Circulation. 2005 May 3;111(17):2274.

17.
18.

Eprosartan improves cardiac performance, reduces cardiac hypertrophy and mortality and downregulates myocardial monocyte chemoattractant protein-1 and inflammation in hypertensive heart disease.

Behr TM, Willette RN, Coatney RW, Berova M, Angermann CE, Anderson K, Sackner-Bernstein JD, Barone FC.

J Hypertens. 2004 Mar;22(3):583-92.

PMID:
15076165
19.

Neurohormonal antagonism in heart failure: what is the optimal strategy?

Sackner-Bernstein JD, Hart D.

Mt Sinai J Med. 2004 Mar;71(2):115-26. Review.

PMID:
15029403
20.

What is the role of biventricular pacing the transplant candidate?

Sackner-Bernstein J, Farmer DM.

Coron Artery Dis. 2004 Mar;15(2):81-5. Review. No abstract available.

PMID:
15024294
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk